This is a commentary describing a novel preclinical approach to engineer microRNAs as cancer therapeutics; it reports no original experimental data, effect sizes, or clinical outcomes.
This is a narrative review synthesizing mechanistic concepts and engineering strategies in preclinical macrophage biology, raising questions about feasibility rather than reporting clinical or definitive translational evidence.
A perspective or review article that raises conceptual questions about mRNA delivery platforms rather than reporting empirical evidence or clinical outcomes.